Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics ...(Flinn Fund for Arizona Proteomics Resear...),Health

Proteomics is a promising and cutting-edge field that studies proteins and their functions in the body. The proteomics production facility will focus on discovering new proteins for the development of diagnostic tests for patients with cancer or other illnesses. These tests could ultimately lead to earlier disease detection and more precise disease management.

Even though the necessary technologies to develop personalized diagnostic tests are available, barriers such as the expense of clinical trials and difficulty obtaining clinical samples have significantly slowed the development process. The Partnership will focus on the development, testing and validation of new molecular diagnostic tools and the approval and distribution of these tools for widespread clinical use. This will be accomplished through a series of collaborative demonstration projects that integrate key health organizations.

The Holy Grail of personalized medicine includes blood-based tests that improve diagnosis and help direct clinical care, said Trent. The unparalleled opportunity the Partnership provides is to expand the magnitude of proteomic studies across a spectrum of key clinical questions.

The Partnership includes recruitment of new faculty and will engage national and international partners to ensure developments are rapidly commercialized.

With the team of scientific and clinical research excellence we are assembling, our goal is to transform medicine from the current one size fits all approach to one that is targeted around a patients unique genetic and molecular profile, Poste said.

Partnerships formed with large health care systems and disease-focused foundations
'/>"/>